Ventritex's Bumpy Ride
Ventritex was an early beneficiary of a more responsive FDA, gaining quick approval to label its implantable cardioverter defibrillator with Cardiac Pacemaker’s leads. Its competitors, however, also benefited.
You may also be interested in...
Effective medical device regulation supports both safety and innovation needs. This article assesses how well the US FDA and the Australian TGA achieve this balance.
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.